title: IDO inhibitors move center stage in immuno-oncology.
authors: Cormac
authors: C
authors: Sheridan
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000276:immunology / Q000627:therapeutic use; D015195:Drug Design; D004345:Drug Industry / Q000639:trends; D004791:Enzyme Inhibitors / Q000276:immunology / Q000627:therapeutic use; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D050503:Indoleamine-Pyrrole 2,3,-Dioxygenase / Q000037:antagonists & inhibitors* / Q000276:immunology*; D009369:Neoplasms / Q000188:drug therapy* / Q000276:immunology*
chemical_list: D000970:Antineoplastic Agents; D004791:Enzyme Inhibitors; D050503:Indoleamine-Pyrrole 2,3,-Dioxygenase